Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis

Journal of Neuroimmunology

Volumn 185, Issue 1-2, 2007, Pages 150-161

  Kakoulidou, Maria ^a   Wang, XiongBiao ^a   Zhao, Xiaoyan ^a   Pirskanen, Ritva ^a   Lefvert, Ann Kari ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Costimulation; Myasthenia gravis; sCD152; sCD28; sCD80; sCD86

Indexed keywords

AZATHIOPRINE; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; SOLUBLE CD152 ANTIGEN; SOLUBLE CD25 ANTIGEN; SOLUBLE CD28 ANTIGEN; SOLUBLE CD80 ANTIGEN; SOLUBLE CD86 ANTIGEN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENERAL ASPECTS OF DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RELIABILITY; SERUM; THYMOMA;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; MYASTHENIA GRAVIS;

EID: 33947695224     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.01.007     Document Type: Article

References (46)

1. Chen Y.Q., and Shi H.Z. CD28/CTLA-4-CD80/CD86 and ICOS-B7RP-1 costimulatory pathway in bronchial asthma. Allergy 61 (2006) 15-26
2. Cohen-Kaminsky S., Jacques Y., Aime C., Safar D., Morel E., and Berrih-Aknin S. Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clin. Immunol. Immunopathol. 62 (1992) 190-198
3. Cohen-Kaminsky S., Jacques Y., Aime C., Safar D., Morel E., and Berrih-Aknin S. Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clin. Immunol. Immunopathol. 62 (1992) 190-198
4. Cohen-Kaminsky S., Devergne O., Delattre R.M., Klingel-Schmitt I., Emilie D., Galanaud P., and Berrih-Aknin S. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur. Cytokine Netw. 4 (1993) 121-132
5. Confalonieri P., Antozzi C., Cornelio F., Simoncini O., and Mantegazza R. Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamma and tumor necrosis factor-alpha levels in patients' serum. J. Neuroimmunol. 48 (1993) 33-36
6. Deng C., Goluszko E., Tuzun E., Yang H., and Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J. Immunol. 169 (2002) 1077-1083
7. Heaney M.L., and Golde D.W. Soluble cytokine receptors. Blood 87 (1996) 847-857
8. Hebbar M., Jeannin P., Magistrelli G., Hatron P.Y., Hachulla E., Devulder B., Bonnefoy J.Y., and Delneste Y. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin. Exp. Immunol. 136 (2004) 388-392
9. Hock B., Starling G., Patton W., Salm N., Bond K., McArthur L., and McKenzie J. Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk. Lymphoma 45 (2004) 2111-2118
10. Hock B.D., Patton W.N., Budhia S., Mannari D., Roberts P., and McKenzie J.L. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 16 (2002) 865-873
11. Hock B.D., Patton W.N., Budhia S., Mannari D., Roberts P., and McKenzie J.L. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 16 (2002) 865-873
12. Huang Y.M., Kivisakk P., Ozenci V., Pirskanen R., and Link H. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin. Exp. Immunol. 118 (1999) 304-308
13. Ip W.K., Wong C.K., Leung T.F., and Lam C.W. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int. Arch. Allergy Immunol. 137 (2005) 45-52
14. Jaretzki III A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., and Sanders D.B. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55 (2000) 16-23
15. Jeannin P., Magistrelli G., Aubry J.P., Caron G., Gauchat J.F., Renno T., Herbault N., Goetsch L., Blaecke A., Dietrich P.Y., Bonnefoy J.Y., and Delneste Y. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 13 (2000) 303-312
16. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., Russell A., Dougados M., Emery P., Nuamah I.F., Williams G.R., Becker J.C., Hagerty D.T., and Moreland L.W. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349 (2003) 1907-1915
17. Lavrnic D., Losen M., Vujic A., De Baets M., Hajdukovic L.J., Stojanovic V., Trikic R., Djukic P., and Apostolski S. The features of myasthenia gravis with autoantibodies to MuSK. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1099-1102
18. Lefvert A.K., Bergstrom K., Matell G., Osterman P.O., and Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J. Neurol. Neurosurg. Psychiatry 41 (1978) 394-403
19. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
20. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., and Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174 (1991) 561-569
21. Linsley P.S., Wallace P.M., Johnson J., Gibson M.G., Greene J.L., Ledbetter J.A., Singh C., and Tepper M.A. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257 (1992) 792-795
22. Liu M.F., Wang C.R., Chen P.C., and Fung L.L. Increased expression of soluble cytotoxic T-lymphocyte-associated antigen-4 molecule in patients with systemic lupus erythematosus. Scand. J. Immunol. 57 (2003) 568-572
23. Liu X., Adams A., Wildt K.F., Aronow B., Feigenbaum L., and Bosselut R. Restricting Zap70 expression to CD4 + CD8 + thymocytes reveals a T cell receptor-dependent proofreading mechanism controlling the completion of positive selection. J. Exp. Med. 197 (2003) 363-373
24. Magistrelli G., Jeannin P., Elson G., Gauchat J.F., Nguyen T.N., Bonnefoy J.Y., and Delneste Y. Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys. Res. Commun. 259 (1999) 34-37
25. Magistrelli G., Jeannin P., Herbault N., Benoit De Coignac A., Gauchat J.F., Bonnefoy J.Y., and Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29 (1999) 3596-3602
26. Oaks M.K., and Hallett K.M. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164 (2000) 5015-5018
27. Oaks M.K., Hallett K.M., Penwell R.T., Stauber E.C., Warren S.J., and Tector A.J. A native soluble form of CTLA-4. Cell. Immunol. 201 (2000) 144-153
28. Obara T., Vodian M.A., and Kung P.C. Clinical significance of soluble interleukin 2 receptor for monitoring the diseases associated with activated lymphocytes and viral infections. J. Clin. Lab. Anal. 6 (1992) 91-104
29. Ostlie N.S., Karachunski P.I., Wang W., Monfardini C., Kronenberg M., and Conti-Fine B.M. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. 166 (2001) 4853-4862
30. Pizzolo G. The soluble interleukin-2 receptor as a new biological marker in diseases. Allergol. Immunopathol. (Madr) 19 (1991) 176-180
31. Poussin M.A., Goluszko E., Hughes T.K., Duchicella S.I., and Christadoss P. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR. J. Neuroimmunol. 111 (2000) 152-160
32. Poussin M.A., Tuzun E., Goluszko E., Scott B.G., Yang H., Franco J.U., and Christadoss P. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J. Immunol. 170 (2003) 4389-4396
33. Rubin L.A., and Nelson D.L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann. Intern. Med. 113 (1990) 619-627
34. Sato S., Fujimoto M., Hasegawa M., Komura K., Yanaba K., Hayakawa I., Matsushita T., and Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 43 (2004) 1261-1266
35. Scott B.G., Yang H., Tuzun E., Dong C., Flavell R.A., and Christadoss P. ICOS is essential for the development of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 153 (2004) 16-25
36. Shi F.D., He B., Li H., Matusevicius D., Link H., and Ljunggren H.G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28 (1998) 3587-3593
37. Shi H.Z., Xie Z.F., Deng J.M., Chen Y.Q., and Xiao C.Q. Soluble CD86 protein in serum samples of patients with asthma. Thorax 59 (2004) 870-875
38. Tesar V., Jelinkova E., Jirsa Jr. M., Bakosova M., Pitha P., and Chabova V. Soluble adhesion molecules and cytokines in patients with myasthenia gravis treated by plasma exchange. Blood Purif. 18 (2000) 115-120
39. van de Stolpe A., and van der Saag P.T. Intercellular adhesion molecule-1. J. Mol. Med. 74 (1996) 13-33
40. Wang X.B., Kakoulidou M., Giscombe R., Qiu Q., Huang D., Pirskanen R., and Lefvert A.K. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130 (2002) 224-232
41. Witkowska A.M., and Borawska M.H. Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. Eur. Cytokine Netw. 15 (2004) 91-98
42. Wong C.K., Lit L.C., Tam L.S., Li E.K., and Lam C.W. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44 (2005) 989-994
43. Wong C.K., Lun S.W., Ko F.W., Ip W.K., Hui D.S., and Lam C.W. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin. Exp. Immunol. 141 (2005) 122-129
44. Zhang G.X., Xiao B.G., Bai X.F., Orn A., van der Meide P.H., and Link H. IFN-gamma is required to induce experimental autoimmune myasthenia gravis. Ann. N.Y. Acad. Sci. 841 (1998) 576-579
45. Zhang G.X., Xiao B.G., Bai X.F., van der Meide P.H., Orn A., and Link H. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162 (1999) 3775-3781
46. Zhang G.X., Xiao B.G., Yu L.Y., van der Meide P.H., and Link H. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. J. Neuroimmunol. 113 (2001) 10-18